Sex hormones unrelated to prostate cancer risk

Having high levels of male sex hormones, known as androgens, has long been hypothesized as a risk factor for prostate cancer. Nearly two dozen prospective studies have examined the relationship between circulating sex hormones and prostate cancer risk, but the results have been inconsistent.

Andrew Roddam, D.Phil., of the University of Oxford in England and colleagues at the Endogenous Hormones and Prostate Cancer Collaborative Group collected the original data from 18 studies and analyzed it to determine the relationship between blood levels of sex hormones and prostate cancer. The pooled data included 3,886 men with prostate cancer and 6,438 controls.

The researchers found no association between prostate cancer risk and blood levels of different forms of testosterone or estrogen.

“The results of this collaborative analysis of the existing worldwide data on the associations between endogenous hormone concentrations and prostate cancer risk indicate that circulating concentrations of androgens and [estrogens] do not appear to be associated with the risk of prostate cancer,” the authors write.

In an accompanying editorial, Paul Godley, M.D., Ph.D., and colleagues at the University of North Carolina at Chapel Hill commend the authors for collaborating on this analysis, and they encourage researchers to use the results as an opportunity to shift the focus of prostate cancer research.

“The study obliges the scientific community to move past a seductive, clinically relevant, and biologically plausible hypothesis and get on with the difficult task of exploring, analyzing, and characterizing modifiable risk factors for prostate cancer,” the editorialists write.

Source: Journal of the National Cancer Institute

Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist
Essential for life in higher animals, vitamin D, once linked to only bone diseases such as rickets and osteoporosis, is now recognized as a major player in contributing to overall human health, emphasizes UC Riverside's Anthony Norman, an international expert on vitamin D.
New risk factor for prostate cancer
(PhysOrg.com) -- The greater the levels of a protein called Insulin-like Growth Factor-1 (IGF-1), the greater the risk of prostate cancer, an Oxford University-led study has found. The results are published in the journal Annals of Internal Medicine.
Researchers study prevention of blood clots in cancer patients
As more individuals with cancer are being treated as outpatients, the University of Rochester Medical Center is working on an emerging problem: how to prevent the life-threatening blood clots that can accompany some newer cancer drugs.
Overweight men face higher risk of dying of prostate cancer
(PhysOrg.com) -- Prostate cancer patients who are overweight and have elevated insulin levels are much more likely to die of the cancer than other patients, say researchers at Harvard University and McGill University. Their research is published in the October issue of The Lancet Oncology.
New catheter-less technique may ease the pain and discomfort of prostate cancer recovery
To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter. The new patentable technique, used in conjunction with robotic prostatectomy -- the surgical removal of the prostate -- eliminates the pain and discomfort associated with the standard catheter.
Raised risk of prostate cancer in Black men
(PhysOrg.com) -- Black men living in England are three times more likely to get prostate cancer than White men and tend to be diagnosed five years younger, researchers have found.
Racial disparities decline for cancer in Missouri
Cancer death rates in the United States are highest among African Americans, but a new report shows that in Missouri the disparity in cancer incidence and death between African Americans and whites is declining. As a result, cancer incidence (the rate of newly diagnosed cases) between the races is equal, although the death rate will probably remain higher for African Americans for some time.
Study: When/if to start hormones for prostate cancer patients whose PSA rises after radiation
A new Fox Chase Cancer Center study suggests men with early stage prostate cancer treated with radiation therapy should begin hormone therapy immediately if their PSA level rises quickly and doubles within six months at any time after treatment. The study also supports foregoing hormones if the PSA doesn't rise as quickly. Both findings suggest a change in the practice of prescribing hormones is warranted.

Sex hormones unrelated to prostate cancer risk

Related stories:

News discussion: